Chardan Healthcare Price, Forecast, Insider, Ratings, Fundamentals & Signals

Philadelphia--(business wire)--renovacor, inc. closes its business combination with chardan healthcare acquisition 2 corp. and will begin trading on the new york stock exchange.

New york, sept. 1, 2021 /prnewswire/ -- chardan healthcare acquisition 2 corp. (nyse: chaq) ("chaq"), a special purpose acquisition company sponsored by chardan capital markets ("chardan"), today announced the results for the proposals considered and voted upon by its stockholders at its special meeting held on september 1, 2021 (the "special meeting"), regarding the proposed business combination with renovacor, inc. ("renovacor"), an early‑stage biotechnology company developing adeno-associated virus (aav)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from bag3 gene variants.

New york, aug. 25, 2021 /prnewswire/ -- renovacor, inc. ("renovacor"), an early–stage biotechnology company developing adeno-associated virus (aav)–based gene therapies for devastating cardiovascular and central nervous system diseases resulting from bag3 gene variants, today announced the appointment of matt killeen, ph.d., as chief scientific officer (cso), effective as of september 1, 2021.

Dr. zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy dr. zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy

New york, march 27, 2021 /prnewswire/ -- juan monteverde , founder and managing partner at monteverde & associates pc, a national securities firm rated top 50 in the 2018 and 2019 iss securities class action services report and headquartered at the empire state building in new york city, is investigating chardan healthcare acquisition 2 corp. ("chaq" or the "company") (chaq) relating to its proposed merger renovacor, inc. under the terms of the agreement, chaq will acquire renovacor through a reverse merger, with renovacor emerging as a publicly traded company. the investigation focuses on whether chardan healthcare acquisition 2 corp. and its board of directors violated securities laws and/or breached their fiduciary duties to the company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. Closes its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange.

NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Capital Markets ("Chardan"), today announced the results for the proposals considered and voted upon by its stockholders at its special meeting held on September 1, 2021 (the "Special Meeting"), regarding the proposed business combination with Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants.

NEW YORK, Aug. 25, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D., as chief scientific officer (CSO), effective as of September 1, 2021.

Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy

NEW YORK, March 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Chardan Healthcare Acquisition 2 Corp. ("CHAQ" or the "Company") (CHAQ) relating to its proposed merger Renovacor, Inc. Under the terms of the agreement, CHAQ will acquire Renovacor through a reverse merger, with Renovacor emerging as a publicly traded company. The investigation focuses on whether Chardan Healthcare Acquisition 2 Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

Nine IPOs and five SPACs went public this past week, and one IPO postponed. New filing activity continued to pump the brakes as we near the election, with just one new IPO filing.

September activity remained high as 11 IPOs and eight SPACs went public this past week. The IPO market shows no signs of slowing with eight IPOs and 18 SPACS submitting initial filings.

KMDA earnings call for the period ending June 30, 2019.

Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors